Hyperimed

A commercial cultivar of Hypericum perforatum included in a 1997–1998 Swiss trial alongside Topas and Elixir. In its first season, Hyperimed showed substantial branching at the base and flower clusters at differing heights. The trial reported vulnerability to anthracnose caused by Colletotrichum gloeosporioides; it should not be treated as a disease-resistant selection.